AzTrials
AzTrials

Healthy AgingSTAMINANCT06145087

Effects of a Supplement to Target Ageing Mechanisms on Vascular Function (STAMINA)

A study testing "NOVOS Core" supplement in people with Healthy Aging and Vascular Dilation, run by University of Surrey at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In the ageing society, extending the healthy lifespan is a major challenge and a healthy diet may play an import role in maintaining health throughout life. With increasing age cardiovascular function declines and large and small blood vessels change in various and complex ways and these changes may lead to many… Read more about this study

Who is it for?
Ages 40 years and olderHealthy volunteers can take part
Conditions the study is for
Healthy Aging, Vascular Dilation
What is being tested?
"NOVOS Core" supplement
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
61 participants
Where
1 siteUnited Kingdom
Study dates
1 Jun 2023to 19 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Generally healthy. (Note: those with stable conditions that do not interfere with the study objectives/procedures will be included at the PI discretion).
  • >40 years
  • Body mass index >20 kg/m2
  • Systolic blood pressure >=120 mmHg
  • Smartphone with step counter

Who cannot join

  • Symptoms of acute infection
  • Cardiac arrhythmias
  • Active malignancy
  • Clinical signs or symptoms of unstable cardiovascular disease (coronary artery disease, lower extremity artery disease, cerebrovascular disease). These include angina pectoris, dyspnoea, palpitation, syncope, claudication, active vasoactive medication.
  • Women who have been pregnant in the last three months, currently pregnant, preparing to become pregnant during the study, or breastfeeding.
  • Those that have undergone a change in hormone-based therapies such as, but not limited to, oral contraceptive pills or progesterone pills within the last 2 months. Progesterone releasing devices are considered hormone-based therapy. Spironolactone is not considered a hormone-based therapy.
Show all 19Show fewer
  • Subjects who are unwilling or unable to comply with the requirements of the protocol.
  • Subjects who have a history of or a current psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study in the opinion of the principal investigator.
  • Subjects with or who have recently experienced traumatic injury, infections, or major surgery at the discretion of the qualified investigator.
  • Subjects who are likely to start taking drugs/medication on a continuous basis or that will undergo surgery during the trial.
  • Subjects engaged in donation or who were recipients of blood products within 90 days before the start of the study.
  • Subjects with alcohol use of more than 2 alcoholic beverages per day within the past month.
  • Subjects participated in a clinical trial with a medicinal, supplemental, nutraceutical or drug within the past two months prior to the first dose in the current study.
  • If participants take fish oil supplements, they will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
  • Subjects using anti-inflammatory drugs on a chronic basis (e.g. aspirin, ibuprofen, diclofenac, celecoxib, etc).
  • Subjects using supplements or substances present in formulation (malate, fisetin, glucosamine, alpha ketoglutaric acid, glycine, theanine, Rhodiola rosea, hyaluronic acid, ginger extract, pterostilbene, lithium). Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
  • Subjects using supplements or substances similar as those used in the formulation (e.g. resveratrol (similar to pterostilbene) or quercetin (similar to fisetin). Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
  • Subjects taking high-dose niacin (nicotinic acid), high-dose vitamin B3, high-dose nicotinamide (niacinamide) within 21 days before the start of the trial. Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial. .
  • Subjects with clinically significant abnormal laboratory results at screening. Known allergy/intolerance to any of the components in the supplement product.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site

  • University of Surrey

    Guildford, GU2 7XH

Other trials in United Kingdom

About this study

Official title: Investigation of Short and Intermediate Term Effects of a Supplement Mix Designed to Target Ageing Mechanisms on Vascular Function in Healthy Middle-aged Participants (STAMINA Study)

In the ageing society, extending the healthy lifespan is a major challenge and a healthy diet may play an import role in maintaining health throughout life. With increasing age cardiovascular function declines and large and small blood vessels change in various and complex ways and these changes may lead to many age-related diseases. On a molecular level, there are many mechanisms that are associated with ageing including cellular senescence, loss of proteostasis, altered cellular communication, genomic instability, epigenetic alterations, telomere shortening, deregulated nutrient sensing, stem cell exhaustion and protein crosslinking. Animal and human studies suggest that dietary supplements may be able to affect these mechanisms. What the effect of the NOVOS Core supplement is on cardiovascular functions is not known.

The aim of the present study is to investigate the short and intermediate term effects of a supplement mix designed to target ageing mechanism on vascular function in healthy middle-aged subjects. (STAMINA Study) The hypothesis is that the supplement will lead to acute and sustained changes in biomarkers of vascular function and health.

60 healthy middle-aged people will be recruited and randomly assigned to either daily intake of the NOVOS Core supplement (n=30) or placebo (n=30) for up to 6 months (3-6). The supplement (NOVOS Core) is a commercially available product and has 12 ingredients. It was developed and is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation. The study will require 2 visits by participants during which non-invasive vascular exams will be performed, venous blood taken and spot urine sample collected. The primary endpoint is change in flow-mediated dilation, secondary endpoints are change in blood pressure, cholesterol, arterial stiffness, microvascular function cardiovascular risk SCORE and daily walking distance. Tertiary endpoints are changes in biomarkers of ageing as assessed in blood samples. Measurements will be taken on the first day before and 2 hours after ingestion of the first supplement or placebo. Participants will consume the supplement or placebo for 6 months and vascular exams and one blood draw will be repeated during the final visit.

Being tested
"NOVOS Core" supplement, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • "NOVOS Core" supplementDietary supplement

    The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.

  • PlaceboDietary supplement

    The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.

Study groups in NCT06145087
Study groupRoleWhat they receive
PlaceboPlacebo comparatorThe placebo is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation.
Receives: Dietary Supplement: Placebo
"NOVOS Core" supplementExperimentalThe "NOVOS Core" supplement is a commercially available product and has 12 ingredients. It was developed and is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation.
Receives: Dietary Supplement: "NOVOS Core" supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in flow-mediated dilation

    Change in flow-mediated dilation with ultrasound (%)

    Measured: 6 months

Secondary outcomes (9)

  1. Change in systolic blood pressure

    Change in systolic blood pressure (mmHg)

    Measured: 6 months

  2. Change in diastolic blood pressure

    Change in diastolic blood pressure (mmHg)

    Measured: 6 months

  3. Change in cholesterol

    Change in cholesterol including LDL, HDL, total cholesterol

    Measured: 6 months

  4. Change in total cholesterol

    Change in total cholesterol (mml/l)

    Measured: 6 months

  5. Change in LDL cholesterol

    Change in LDL cholesterol (mmol/l)

    Measured: 6 months

  6. Change in HDL cholesterol

    Change in HDL cholesterol (mmol/l)

    Measured: 6 months

  7. Change in arterial stiffness

    Change in pulse wave velocity (m/s)

    Measured: 6 months

  8. Change in daily walking distance

    Change in daily walking distance in kilometers as measure by personal smartphone

    Measured: 6 months

  9. Change in cardiovascular risk

    Change in calculated 10 year cardiovascular risk (European Society of Cardiology Systematic Coronary Risk Evaluation [ESC SCORE])

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2023
  2. Study start1 Jun 2023
  3. Primary completion5 Aug 2025
  4. Study completion19 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
two-armed parallel group, randomised, controlled, double-blind clinical trial.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
61 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06145087
Sponsor's protocol ID
STAMINA_Protocol_V4.0
Acronym
STAMINA
Status last verified
Jan 2026
First submitted
7 Mar 2023
Last updated
22 Jan 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Piercy C, Harris J, Sackho K, Campagnolo P, Barardo D, Creagh-Brown B, Heiss C. Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial. Eur Heart J Open. 2026 Nov 4;6(6):oeag157. doi: 10.1093/ehjopen/oeag157. eCollection 2026 Nov.

    PubMed 42979377

Questions about this trial

What is this clinical trial studying?

A study testing "NOVOS Core" supplement in people with Healthy Aging and Vascular Dilation, run by University of Surrey at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in flow-mediated dilation (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06145087, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in